Unlocking the mysteries of many women’s health concerns
Women all over the world should have the chance to live their best lives. And since good health is the best place to start, Roche is empowering women with the knowledge and tools they need to flourish.
All women should have control over their health, but they don’t always have the same access to healthcare—and access can be essential to saving or losing lives. Roche is, therefore, leading the way in the revolution for diagnostics that transform healthcare, making its reach more universal but its perspective more individual.
Our promise to women
We get closer every day to unlocking the mysteries of many women’s health concerns, but there have historically been gaps. Under the guise of modesty, female patients weren’t thoroughly examined, nor were women’s illnesses prioritized for study. Clinical trials focused mostly on men. And despite distinct male and female medical needs, even for sicknesses shared by both, gender-specific responses were disregarded when creating treatments and unraveling pathologies.
For these reasons, Roche is committed to innovations in diagnostics that enable women in their health journeys with the information they and their clinicians need to make treatment decisions that are right for them.
Real solutions to real problems
At Roche, we are achieving this goal by turning molecular research into tangible solutions. Our sequencing diagnostics have the power to generate vast amounts of personalized data, which can then be integrated with other patient information to provide a more complete health picture.
Providing physicians with decision support tools using this aggregated information can lead to intervention before symptoms present themselves and illness spreads.
Because 1 in every 6 couples globally has trouble conceiving, we created a non-invasive blood test that reveals approximately how many eggs remain in a woman’s ovaries.
For pregnant women, we have diagnostics solutions that can provide peace of mind and prevent unnecessary hospitalizations.The sFlt-1/PIGF ratio of biomarkers is derived from a simple blood test and can predict with 99% certainty if a mother-to-be will develop preeclampsia within one week. It can additionally rule out if the condition will develop within the next four weeks. We also have a portfolio of prenatal diagnostics for checking in on the baby, including a blood test that can non-invasively define the risk of chromosomal abnormalities
With our advanced breast cancer diagnostics, we helped propel a portfolio of innovative treatments for an invasive cancer affecting more than 250,000 women around the world each year.
Bridge to a healthier future
We believe women everywhere should have access to precise information about their health as early as possible. Roche is committed to transforming healthcare to serve the women who need it and to provide the right diagnostics and decision support solutions so women can take charge of their health at every stage of their lives.
The value of diagnostics shines through in the way it improves the lives of millions of women around the world. Preventive screening, early detection, and guidance for personalized treatments help women thrive and be their best selves.